FHJ95411
Human
Mouse
IgG1, kappa
Monoclonal
FITC
CD89, Immunoglobulin alpha Fc receptor, FCAR, IgA Fc receptor
0.5 mg/ml
Please contact with the lab for this information.
FCM
Liquid
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Store at 4°C for 12 months. Protect from light. Do not freeze.
26D6
Enrichment of human IgA-coated bacterial vesicles in ulcerative colitis as a driver of inflammation., PMID:40301356
Targeting ALPPL2 with a novel CD89 bispecific antibody reprograms macrophages to enhance anti-tumor immunity., PMID:40209501
Enhancing activity of FcαRI-bispecific antibodies using glycoengineering., PMID:40156381
Circulating mucosal-like IgA responses increase with severity of Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome., PMID:39512345
The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy., PMID:39358557
Blood soluble CD89-IgA complex may be a potential biomarker for predicting multi-organ involvement, especially renal involvement in children with immunoglobulin A vasculitis., PMID:39241523
ITPK1 Sensitizes Tumor Cells to IgA-dependent Neutrophil Killing In Vivo., PMID:39213127
Invasive and Non-invasive Clinical Haemophilus influenzae Type A Isolates Activate Differentiated HL-60 Cells In Vitro., PMID:38774126
FcαRI (CD89) is upregulated on subsets of mucosal and circulating NK cells and regulates IgA-class specific signaling and functions., PMID:38677592
The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis., PMID:38536935
SIgA structures bound to Streptococcus pyogenes M4 and human CD89 provide insights into host-pathogen interactions., PMID:37872175
DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection., PMID:37639455
IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models., PMID:37479484
Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains., PMID:37338671
Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody., PMID:37126928
Prior COVID-19 Immunization Does Not Cause IgA- or IgG-Dependent Enhancement of SARS-CoV-2 Infection., PMID:37112685
Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity., PMID:37081893
Current Status and Perspectives on Recurrent IgA Nephropathy after Kidney Transplantation., PMID:36966530
Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA., PMID:36817447
Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade., PMID:36460336
Fcα Receptor-1-Activated Monocytes Promote B Lymphocyte Migration and IgA Isotype Switching., PMID:36232432
Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer., PMID:35854649
Anti-FcαRI Monoclonal Antibodies Resolve IgA Autoantibody-Mediated Disease., PMID:35371001
Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case., PMID:34997322
Therapeutic exploitation of neutrophils to fight cancer., PMID:34922817
Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy., PMID:34756952
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma., PMID:34716207
Fecal Microbiota Transplantation Modulates Renal Phenotype in the Humanized Mouse Model of IgA Nephropathy., PMID:34712223
Poly-IgA Complexes and Disease Severity in IgA Nephropathy., PMID:34607844
IgA Immune Complexes Induce Osteoclast-Mediated Bone Resorption., PMID:34276648
Are there animal models of IgA nephropathy?, PMID:34230994
IgA vasculitis., PMID:34170395
IgA and FcαRI: Versatile Players in Homeostasis, Infection, and Autoimmunity., PMID:33447585
Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials., PMID:33197478
Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon-γ., PMID:33193394
Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41., PMID:32582208
Food antigens and Transglutaminase 2 in IgA nephropathy: Molecular links between gut and kidney., PMID:32135400
Immunological Pattern in IgA Nephropathy., PMID:32085673
Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History., PMID:32076466
IgA: Structure, Function, and Developability., PMID:31817406
Serum IgA Fc effector functions in infectious disease and cancer., PMID:31785006
Mesangial Deposition Can Strongly Involve Innate-Like IgA Molecules Lacking Affinity Maturation., PMID:31227634
Topical application of human-derived Ig isotypes for the control of acute respiratory infection evaluated in a human CD89-expressing mouse model., PMID:31105268
Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG., PMID:31031746
CD89 Is a Potent Innate Receptor for Bacteria and Mediates Host Protection from Sepsis., PMID:30995475
IgA and FcαRI: Pathological Roles and Therapeutic Opportunities., PMID:30984170
FcαRI Dynamics Are Regulated by GSK-3 and PKCζ During Cytokine Mediated Inside-Out Signaling., PMID:30766540
IgA nephropathy: clearance kinetics of IgA-containing immune complexes., PMID:30218212
Murine Models of Human IgA Nephropathy., PMID:30177023
IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis., PMID:29651286
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
